Early Treatment With Rasagiline May Slow Parkinson's Disease Decline

He also suggested that further observation of the cohort may be able to determine the reason the higher dose did not appear to provide benefit in this study. It’s possible, he said, that the early- and delayed-start groups may separate over time.

“Finally,” he asked, “based on these results, how do we decide to use rasagiline in our routine practice?” Dr. Olanow didn’t provide an answer but concluded by saying, “I think this is a remarkable study, and I think it will bring forth much discussion in the months ahead.” He also predicted that the manufacturer, Teva Pharmaceuticals, is likely to seek a new indication for the drug from the FDA, for disease modification in early Parkinson’s disease.